ANP, BNP and CNP: Physiology and Pharmacology of the Cardiorenal Axis

Textbook of Nephro-Endocrinology

Volumn , Issue , 2009, Pages 287-307

  Lee, Candace Y W ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882508533     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373870-7.00020-X     Document Type: Chapter

References (207)

1. Adams K.F., Lindenfeld J., Arnold J.M.O., et al. HFSA 2006 comprehensive heart failure practice guidelines. J Card Fail 2006, 12:e1-e122.
2. Ahluwalia A., Hobbs A.J. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 2005, 26:162-167.
3. Airhart N., Yang Y.F., Roberts C.T., Silberbach M. Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction. J Biol Chem 2003, 278:38693-38698.
4. Akerman M.J., Yaegashi M., Khiangte Z., Murugan A.T., Abe O., Marmur J.D. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest 2006, 130:66-72.
5. Allgren R.L., Marbury T.C., Rahman S.N., et al. Anaritide in acute tubular necrosis. N Engl J Med 1997, 336:828-834.
6. Anand-Srivastava M.B. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005, 26:1044-1059.
7. Angus R.M., McCallum M.J., Hulks G., Thomson N.C. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 1993, 147:1122-1125.
8. Ardaillou N., Nivez M.P., Ardaillou R. Stimulation of cyclic GMP synthesis in human cultured glomerular cells by atrial natriuretic peptide. FEBS Lett 1986, 204:177-182.
9. Arora R.R., Venkatesh P.K., Molnar J. Short and long-term mortality with nesiritide. Am Heart J 2006, 152:1084-1090.
10. Banga, A.K. (2006). Oral delivery of peptide and protein drugs. In Therapeutic peptides and proteins: formulation, processing, and delivery systems, 2nd edn. CRC Press, Boca Raton, pp. 229-258.
11. Baxter G.F. Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol 2004, 99:90-93.
12. Beaver T.M., Winterstein A.G., Shuster J.J., et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin Cardiol 2006, 29:18-24.
13. Best P.J., Burnett J.C., Wilson S.H., Holmes D.R., Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002, 55:375-384.
14. Bibbins-Domingo K., Gupta R., Na B., Wu A.H., Schiller N.B., Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. J Am Med Assoc 2007, 297:169-176.
15. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., Lapp H., Stasch J.-P., Burnett J.C. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007, 49:1128-1133.
16. Boerrigter G., Costello-Boerrigter L.C., Harty G.J., Lapp H., Burnett J.C. Des-Serine-Proline B-Type natriuretic peptide (BNP 3-32) in cardiorenal regulation. Am J Physiol Renal Fluid Electrolyte Physiol 2007, 292:R897-R901.
17. Borgeson D.D., Stevens T.L., Heublein D.M., Matsuda Y., Burnett J.C. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci (Lond.) 1998, 95:195-202.
18. Bryan P.M., Xu X., Dickey D.M., Chen Y., Potter L.R. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol 2007, 292:F1636-F1644.
19. Burley D.S., Ferdinandy P., Baxter G.F. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007, 152:855-869.
20. Burley D.S., Hamid S.A., Baxter G.F. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 2007.
21. Burnett J.C., Kao P.C., Hu D.C., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986, 231:1145-1147.
22. Burnett J.C., Costello-Boerrigter L., Boerrigter G. Alterations in the kidney in heart failure: The cardiorenal axis in the regulation of sodium homeostasis. Heart failure: a companion to Braunwald's heart disease 2004, 279-289. Elsevier Inc., Philadelphia. D.L. Mann (Ed.).
23. Canaan-Kuhl S., Jamison R.L., Myers B.D., Pratt R.E. Identification of 'B' receptor for natriuretic peptide in human kidney. Endocrinology 1992, 130:550-552.
24. Candido R., Burrell L.M., Jandeleit-Dahm K.A.M., Cooper M.E. Vasoactive peptides and the kidney. Brenner & Rector's the kidney 2008, 333-362. Saunders, Philadelphia. 8th edn. B.M. Brenner (Ed.).
25. Carstens J., Jensen K.T., Pedersen E.B. Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther 1998, 64:73-86.
26. Castro L.R., Verde I., Cooper D.M., Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006, 113:2221-2228.
27. Cataliotti A., Giordano M., De Pascale E., et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol 2002, 283:F464-F472.
28. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680-1685.
29. Cataliotti A., Schirger J.A., Martin F.L., et al. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation 2005, 112:836-840.
30. Cataliotti A., Heublein D.M., James K.D., Burnett J.C. Biological actions of a novel oral human BNP in an experimental model of acute hypertension (abst). J Card Fail 2006, (12 Suppl 1):S30-14.
31. Cataliotti A., Chen H.H., James K.D., Burnett J.J.C. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med 2007, 17:10-14.
32. Charles C.J., Espiner E.A., Richards A.M., Nicholls M.G., Yandle T.G. Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. Am J Physiol 1995, 268:R201-R207.
33. Chen H.H. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!. J Am Coll Cardiol 2007, 49:1089-1091.
34. Chen H.H., Burnett J.C. Clinical application of the natriuretic peptides in heart failure. Eur Heart J 2006, 8(Suppl E):E18-E25.
35. Chen H.H., Grantham J.A., Schirger J.A., Jougasaki M., Redfield M.M., Burnett J.C. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000, 36:1706-1712.
36. Chen H.H., Lainchbury J.G., Burnett J.C. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002, 40:1186-1191.
37. Chen H.H., Redfield M.M., Nordstrom L.J., Horton D.P., Burnett J.C. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004, 10:115-119.
38. Chen H.H., Cataliotti A., Schirger J.A., Martin F.L., Burnett J.C. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1093-R1097.
39. Chen H.H., Huntley B.K., Schirger J.A., Cataliotti A., Burnett J.C. Maximizing the renal cyclic 3(-5(-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 2006, 17:2742-2747.
40. Chen H.H., Cataliotti A., Martin F.L., Schirger J.A., Burnett J.C. AlbuBNP, a recombinant human B-type natriuretic peptide and serum albumin fusion hormone has prolonged natriuretic, glomerular filtration rate enhancing and aldosterone inhibiting properties (abst). J Card Fail 2006, 12(Suppl 1):S84.
41. Chen H.H., Pan S., Burnett J.C., Simari R.D. A novel designer natriuretic and diuretic peptide based upon an alternatively spliced BNP without vascular vasodilatory actions (abst). Circulation 2006, 114(Suppl II):II-270.
42. Chen H.H., Sundt T.M., Cook D.J., Heublein D.M., Burnett J.C. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007, 116(suppl):I-134-I-138.
43. Clavell A.L., Stingo A.J., Wei C.M., Heublein D.M., Burnett J.C. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993, 264:R290-R295.
44. Clemens L.E., Almirez R.G., Baudouin K.A., Mischak R.P., Grossbard E.B., Protter A.A. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. J Pharmacol Exp Ther 1998, 287:67-71.
45. Clerico A., Recchia F.A., Passino C., Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: Physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-29.
46. Cody R.J., Atlas S.A., Laragh J.H., et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362-1374.
47. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000, 343:246-253. For the Nesiritide Study Group.
48. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981, 28:89-94.
49. Dean A.D., Vehaskari V.M., Greenwald J.E. Synthesis and localization of C-type natriuretic peptide in mammalian kidney. Am J Physiol 1994, 266:F491-F496.
50. Dean, A.D., Vehaskari, V.M., Ritter, D. and Greenwald, J.E. (1996). Distribution and regulation of guanylyl cyclase type B in the rat nephron. In F311-8.
51. Del Ry S., Passino C., Emdin M., Giannessi D. C-type natriuretic peptide and heart failure. Pharmacol Res 2006, 54:326-333.
52. Dickey D.M., Flora D.R., Bryan P.M., et al. Differential regulation of membrane guanylyl cyclases in congestive heart failure: NPR-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007, 148:3518-3522.
53. Dorner G.T., Selenko N., Kral T., Schmetterer L., Eichler H.G., Wolzt M. Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. Clin Pharmacol Ther 1998, 64:322-330.
54. D'Souza S.P., Yellon D.M., Martin C., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003, 284:H1592-H1600.
55. Eiskjaer H., Pedersen E.B. Dose-response study of atrial natriuretic peptide bolus injection in healthy man. Eur J Clin Invest 1993, 23:37-45.
56. Espiner E.A., Prickett T.C., Yandle T.G., et al. ABCs of natriuretic peptides: growth. Horm Res 2007, 67(Suppl 1):81-90.
57. Feldman D.S., Ikonomidis J.S., Uber W.E., et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004, 10:292-296.
58. Fischmeister R., Castro L.R.V., Abi-Gerges A., et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006, 99:816-828.
59. Fluge T., Fabel H., Wagner T.O., Schneider B., Forssmann W.G. Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Eur J Clin Invest 1995, 25:728-736.
60. Forfia P.R., Lee M., Tunin R.S., Mahmud M., Champion H.C., Kass D.A. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007, 49:1079-1088.
61. Forssmann W., Meyer M., Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001, 51:450-462.
62. Frokjaer S., Otzen D.E. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005, 4:298-306.
63. Furuya M., Ohnuma N., Takehisa M., et al. Pharmacological activities of brain natriuretic peptides of human, porcine and rat origin. Eur J Pharmacol 1991, 200:233-237.
64. Furuya M., Tawaragi Y., Minamitake Y., et al. Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1992, 183:964-969.
65. Garbers D.L., Chrisman T.D., Wiegn P., et al. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab 2006, 17:251-258.
66. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
67. Giles T.D., Quiroz A.C., Roffidal L.E., Marder H., Sander G.E. Prolonged hemodynamic benefits from a high-dose bolus injection of human atrial natriuretic factor in congestive heart failure. Clin Pharmacol Ther 1991, 50:557-563.
68. Goetz K., Drummer C., Zhu J.L., Leadley R., Fiedler F., Gerzer R. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J Am Soc Nephrol 1990, 1:867-874.
69. Gordon G.R., Schumann R., Rastegar H., Khabbaz K., England M.R. Nesiritide for treatment of perioperative low cardiac output syndromes in cardiac surgical patients: an initial experience. J Anesth 2006, 20:307-311.
70. Groban L., Cowley A.W., Ebert T.J. Atrial natriuretic peptide augments forearm capillary filtration in humans. Am J Physiol 1990, 259:H258-H263.
71. Gunning M., Silva P., Brenner B.M., Zeidel M.L. Characteristics of ANP-sensitive guanylate cyclase in inner medullary collecting duct cells. Am J Physiol 1989, 256:F766-F775.
72. Haneda M., Kikkawa R., Koya D., et al. Biological receptors mediate anti-proliferative action of atrial natriuretic peptide in cultured mesangial cells. Biochem Biophys Res Commun 1993, 192:642-648.
73. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
74. Harris P.J., Thomas D., Morgan T.O. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987, 326:697-698.
75. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005, 102:17442-17447.
76. Heublein D.M., Huntley B.K., Boerrigter G., et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007, 49:1114-1119.
77. Heywood J.T., Ho A., Mathur V. Favorable renal hemodynamic effects of intra-renal nesiritide infusion in heart transplant patients (abst). J Card Fail 2006, 12 (Suppl 1):S3.
78. Hillock, R.J., Frampton, C.M., Yandle, T.G., Troughton, R.W., Lainchbury, J.G., and Richards, A.M. (2007). B-Type natriuretic peptide infusions in acute myocardial infarction. Heart published online July 16, 2007. Accessed July 17, 2007.
79. Hirsch J.R., Meyer M., Forssmann W.G. ANP and urodilatin: who is who in the kidney. Eur J Med Res 2006, 11:447-454.
80. Hobbs A., Foster P., Prescott C., Scotland R., Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: Novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004, 110:1231-1235.
81. Horio T., Tokudome T., Maki T., et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003, 144:2279-2284.
82. Hunt P.J., Richards A.M., Espiner E.A., Nicholls M.G., Yandle T.G. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994, 78:1428-1435.
83. Hunt P.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996, 81:3871-3876.
84. Huntley B.K., Sandberg S.M., Noser J.A., et al. BNP-induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 2006, 209:943-949.
85. Jensen K.T., Carstens J., Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998, 274:F63-72.
86. Jensen K.T., Eiskjaer H., Carstens J., Pedersen E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 1999, 96:5-15.
87. John S.W., Veress A.T., Honrath U., et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 1996, 271:R109-R114.
88. Johns D.G., Ao Z., Heidrich B.J., et al. Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun 2007, 358:145-149.
89. Jorgensen L., Moeller E.H., van de Weert M., Nielsen H.M., Frokjaer S. Preparing and evaluating delivery systems for proteins. Eur J Pharmaceut Sci 2006, 29:174-182.
90. Kasama S., Toyama T., Hatori T., et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007, 49:667-674.
91. Kato T., Muraski J., Chen Y., et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005, 115:2716-2730.
92. Keating G.M., Goa K.L. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003, 63:47-70.
93. Kelsall C.J., Chester A.H., Amrani M., Singer D.R.J. C-type natriuretic peptide relaxes human coronary artery bypass grafts preconstricted by endothelin-1. Ann Thorac Surg 2005, 80:1347-1351.
94. Kelsall C.J., Chester A.H., Sarathchandra P., Singer D.R.J. Expression and localization of C-type natriuretic peptide in human vascular smooth muscle cells. Vasc Pharmacol 2006, 45:368-373.
95. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993, 291:83-88.
96. Kimura K., Yamaguchi Y., Horii M., et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007.
97. Kitakaze M., Asakura M., Shintani Y., et al. Large-scale trial using atrial natriuretic peptide or nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction [abst]. Circulation 2006, 114:2425-2426. On behalf of the J-WIND Investigators.
98. Kitakaze M., Asakura M., Kim J., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007, 370:1483-1493.
99. Koike J., Nonoguchi H., Terada Y., Tomita K., Marumo F. Effect of urodilatin on cGMP accumulation in the kidney. J Am Soc Nephrol 1993, 3:1705-1709.
100. Kudo T., Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 1984, 312:756-757.
101. Lee C.Y.W., Burnett J.C. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007, 12:131-142.
102. Lee C.Y.W., Burnett J.C. Discovery of a novel synthetic natriuretic peptide, CU-NP (abst). J Card Fail 2007, 13(Suppl 2):S74.
103. Lee C.Y., Burnett J.C. Design, synthesis, and pharmacologic actions of a novel designer natriuretic peptide: CU-NP (abst). Circulation 2007, 116(Suppl II):II 549-II 550.
104. Lee E.Y., Humphreys M.H. Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol 1996, 271:F3-6.
105. Lee C.Y., Boerrigter G., Harty G.J., Lisy O., Burnett J.C. Pharmacodynamic profile of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide (abst). Circulation 2007, 116(Suppl II):II 550.
106. Lewis J., Salem M.M., Chertow G.M., et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000, 36:767-774.
107. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007, 49:1071-1078.
108. Lindenfeld J., Schrier R.W. The kidney in heart failure. Congestive heart failure 2007, 243-260. Lippincott Williams & Wilkins, Philadelphia. 3rd edn. J.D. Hosenpud, B.H. Greenberg (Eds.).
109. Lisy O., Burnett J.C. The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP (abst). J Am Coll Cardiol 2003, (41 Suppl 1):312A.
110. Lisy O., Burnett J.C. The new designer peptide CD-NP unloads the heart, suppresses renin and is natriuretic in vivo (abst). J Card Fail 2003, 9(Suppl 1):S32.
111. Lisy O., Jougasaki M., Heublein D.M., et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999, 56:502-508.
112. Lisy O., Lainchbury J.G., Leskinen H., Burnett J.C. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001, 37:1089-1094.
113. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., Burnett J.C. Design, synthesis and unique biological actions of CD-NP: a novel CNP-like chimeric natriuretic peptide (abst). Circulation 2006, (114 Suppl II):II-440.
114. Loretz C.A., Pollina C. Natriuretic peptides in fish physiology. Comp Biochem Physiol Part A: Mol Integ Physiol 2000, 125:169-187.
115. Maeda K., Tsutamoto T., Wada A., et al. Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction. J Appl Physiol 2000, 89:458-464.
116. Margulies K.B., Heublein D.M., Perrella M.A., Burnett J.C. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol 1991, 260:F562-F568.
117. Martin F.L., Supaporn T., Chen H.H., et al. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. Am J Physiol Regul Integr Comp Physiol 2007, 293:R1580-R1585.
118. Mattingly M.T., Brandt R.R., Heublein D.M., Wei C.M., Nir A., Burnett J.C. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 1994, 46:744-747.
119. Meirhaeghe A., Sandhu M.S., McCarthy M.I., et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 2007, 16:1343-1350.
120. Mentzer R.M., Oz M.C., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA Trial. J Am Coll Cardiol 2007, 49:716-726.
121. Miller M.A., Malkar N.B., Severynse-Stevens D., et al. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: In vitro activity screening. Bioconjug Chem 2006, 17:267-274.
122. Millul V., Ardaillou N., Placier S., Baudouin B., Ronco P.M. Receptors for natriuretic peptides in a human cortical collecting duct cell line. Kidney Int 1997, 51:281-287.
123. Mitrovic V., Luss H., Nitsche K., et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005, 150:1239.e1-1239.e8.
124. Mitrovic V., Seferovic P.M., Simeunovic D., et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832.
125. Moazami N., Oz M.C. Natriuretic peptides in the perioperative management of cardiac surgery patients. Heart Surg Forum 2005, 8:E151-E157.
126. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
127. Nakao K. Translational research of natriuretic peptide family (abst). BMC Pharmacol 2007, (7 Suppl 1):S32-S38.
128. Nakao K., Sugawara A., Morii N., et al. The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol 1986, 31:101-103.
129. Nir A., Beers K.W., Clavell A.L., et al. CNP is present in canine renal tubular cells and secreted by cultured opossum kidney cells. Am J Physiol 1994, 267:R1653-R1657.
130. Obata H., Yanagawa B., Tanaka K., et al. CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis. Biochem Biophys Res Commun 2007, 356:60-66.
131. Ohno N., Itoh H., Ikeda T., et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2005, 105:1623-1626.
132. Padilla F., Garcia-Dorado D., Agullo L., et al. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001, 51:592-600.
133. Pagel-Langenickel I., Buttgereit J., Bader M., Langenickel T.H. Natriuretic peptide receptor B signaling in the cardiovascular system: Protection from cardiac hypertrophy. J Mol Med 2007, 85:797-810.
134. Pankow K., Wang Y., Gembardt F., et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007, 101:875-882.
135. Pasut G., Morpurgo M., Veronese F.M. Basic strategies for PEGylation of peptid and protein drugs. Delivery of protein and peptide drugs in cancer 2006, 53-84. Imperial College Press, London. V.P. Torchilin (Ed.).
136. Patel J.B., Valencik M.L., Pritchett A.M., Burnett J.C., McDonald J.A., Redfield M.M. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005, 289:H777-H784.
137. Pejchalova, K., Krejci, P. and Wilcox, W.R. (2008). C-natriuretic peptide: An important regulator of cartilage. Mol Genet Metab. In Press.
138. Peltonen T.O., Taskinen P., Soini Y., et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 2007, 116:1283-1289.
139. Pham I., Sediame S., Maistre G., et al. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol Regul Integr Comp Physiol 1997, 273:R1457-R1464.
140. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006, 27:47-72.
141. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). (2002). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J Am Med Assoc 287, 1531-40; Erratum, J Am Med Assoc 288, 577.
142. Rautureau Y., Baxter G.F. Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium. Curr Pharm Des 2004, 10:2477-2482.
143. Richards A.M. Atrial natriuretic factor administered to humans: 1984-1988. J Cardiovasc Pharmacol 1989, 13(Suppl 6):S69-74.
144. Richards A.M., Espiner E.A., Ikram H., Yandle T.G. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels. Hypertension 1989, 14:261-268.
145. Richards A.M., Crozier I.G., Holmes S.J., Espiner E.A., Yandle T.G., Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens 1993, 11:163-170.
146. Riter H.G., Redfield M.M., Burnett J.C., Chen H.H. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction (letter). J Am Coll Cardiol 2006, 47:2334-2335.
147. Saba S.R., Vesely D.L. Cardiac natriuretic peptides: hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium, and fibroblasts of human cancers. Histol Histopathol 2006, 21:775-783.
148. Sabrane K., Kruse M.N., Fabritz L., et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005, 115:1666-1674.
149. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
150. Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J Am Med Assoc 2005, 293:1900-1905.
151. Sackner-Bernstein J.D., Skopicki H., Aaronson K.D. Natriuretic peptides for the treatment of heart failure. Heart failure: pharmacologic management 2006, 154-171. Blackwell Publishing, Malden. A. Feldman (Ed.).
152. Salzberg S.P., Filsoufi F., Anyanwu A., et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 2005, 80:502-506.
153. Sato K., Sekiguchi S., Kawagishi N., et al. Continuous low-dose human atrial natriuretic peptide promotes diuresis in oliguric patients after living donor liver transplantation. Transplant Proc 2006, 38:3591-3593.
154. Schulz S. C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides 2005, 26:1024-1034.
155. Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W.G. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988, 66:752-759.
156. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992, 267:13928-13932.
157. Scotland R.S., Cohen M., Foster P., et al. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005, 102:14452-14457.
158. Sengenes C., Berlan M., De Glisezinski I., Lafontan M., Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. Faseb J 2000, 14:1345-1351.
159. Sezai A., Shiono M., Orime Y., et al. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000, 69:732-738.
160. Sezai A., Hata M., Wakui S., et al. Efficacy of low-dose continuous infusion of alpha-human atrial natriuretic peptide (hANP) during cardiac surgery: possibility of postoperative left ventricular remodeling effect. Circ J 2006, 70:1426-1431.
161. Sezai A., Shiono M., Hata M., et al. Efficacy of continuous low-dose human atrial natriuretic peptide given from the beginning of cardiopulmonary bypass for thoracic aortic surgery. Surg Today 2006, 36:508-514.
162. Sezai A., Hata M., Wakui S., et al. Efficacy of low-dose continuous infusion of alpha-human atrial natriuretic peptide (hANP) during cardiac surgery. Circ J 2006, 70:1426-1431.
163. Sezai A., Hata M., Wakui S., et al. Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome. Circ J 2007, 71:1401-1407.
164. Singh G., Kuc R.E., Maguire J.J., Fidock M., Davenport A.P. Novel snake venom ligand Dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: Downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006, 99:183-190.
165. Soeki T., Kishimoto I., Okumura H., et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005, 45:608-616.
166. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
167. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990, 168:863-870.
168. Suga S., Nakao K., Itoh H., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of 'vascular natriuretic peptide system'. J Clin Invest 1992, 90:1145-1149.
169. Supaporn T., Sandberg S.M., Borgeson D.D., et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 1996, 50:1718-1725.
170. Suwa M., Seino Y., Nomachi Y., Matsuki S., Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 2005, 69:283-290.
171. Sward K., Valson F., Ricksten S.E. Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand 2001, 45:536-542.
172. Sward K., Valsson F., Odencrants P., Samuelsson O., Ricksten S.E. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004, 32:1310-1315.
173. Tan A.C., Russel F.G., Thien T., Benraad T.J. Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 1993, 24:28-45.
174. Terada Y., Tomita K., Nonoguchi H., Yang T., Marumo F. PCR localization of C-type natriuretic peptide and B-type receptor mRNAs in rat nephron segments. Am J Physiol 1994, 267:F215-F222.
175. Tokudome T., Horio T., Soeki T., et al. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: Interference between CNP and endothelin-1 signaling pathways. Endocrinology 2004, 145:2131-2140.
176. Tonolo G., McMillan M., Polonia J., et al. Plasma clearance and effects of alpha-hANP infused in patients with end-stage renal failure. Am J Physiol 1988, 254:F895-F899.
177. Tonolo G., Richards A.M., Manunta P., et al. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation 1989, 80:893-902.
178. Totsune K., Takahashi K., Murakami O., et al. Natriuretic peptides in the human kidney. Hypertension 1994, 24:758-762.
179. Tsuruda T., Boerrigter G., Huntley B.K., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002, 91:1127-1134.
180. van den Akker F. Structural insights into the ligand binding domains of membrane bound guanylyl cyclases and natriuretic peptide receptors. J Mol Biol 2001, 311:923-937.
181. Vesely B.A., Eichelbaum E.J., Alli A.A., Sun Y., Gower W.R., Vesely D.L. Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers. Eur J Clin Invest 2006, 36:810-819.
182. Volpe M., Tritto C., De Luca N., et al. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest 1991, 88:1481-1489.
183. Wang W., Ou Y., Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004, 21:2105-2111.
184. Wang Y., de Waard M.C., Sterner-Kock A., et al. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 2007, 9:548-557.
185. Weidmann P., Hasler L., Gnadinger M.P., et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986, 77:734-742.
186. + antiport in proximal tubular brush border membrane: role of dopamine. Kidney Int 1990, 38:1133-1140.
187. Wu C., Wu F., Pan J., Morser J., Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem 2003, 278:25847-25852.
188. Xia, W., Mruk, D.D. and Cheng, C.Y. (2007). C-type natriuretic peptide regulates blood-testis barrier dynamics in adult rat testes. In 3841-6.
189. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 2000, 97:8525-8529.
190. Yancy C., Massie B., Krum H., Silver M., Stevenson L., Mills R. Chronic serial infusion of nesiritide is not associated with worsening renal function in chronic decompensated heart failure patients with renal insufficiency: An analysis from the FUSION-II Trial (abst). J Card Fail 2007, 13:S136.
191. Yang X.M., Philipp S., Downey J.M., Cohen M.V. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006, 101:311-318.
192. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
193. Zeidel M.L., Seifter J.L., Lear S., Brenner B.M., Silva P. Atrial peptides inhibit oxygen consumption in kidney medullary collecting duct cells. Am J Physiol 1986, 251:F379-F383.
194. Zeidel M.L., Silva P., Brenner B.M., Seifter J.L. cGMP mediates effects of atrial peptides on medullary collecting duct cells. Am J Physiol 1987, 252:F551-F559.
195. Zeidel M.L., Kikeri D., Silva P., Burrowes M., Brenner B.M. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest 1988, 82:1067-1074.
196. Zhao J., Ardaillou N., Lu C.Y., et al. Characterization of C-type natriuretic peptide receptors in human mesangial cells. Kidney Int 1994, 46:717-725.
197. Zierer A., Voeller R.K., Melby S.J., et al. Potential renal protective benefits of intra-operative BNP infusion during cardiac transplantation. Transplant Proc 2006, 38:3680-3684.
198. Chen H.H., Schirger J.A., Cataliotti A., Burnett J.C. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail 2006, 8:681-686.
199. Chen H.H., Schirger J.A., Alessandro C., Martin F.L., Burnett J.C. Intra-renal infusion of BNP in experimental heart failure: a novel strategy to maximize the renal enhancing actions of BNP while minimizing arterial hypotension (abst). J Card Fail 2006, (12 Suppl 1):S32.
200. Redfield M.M., Edwards B.S., Heublein D.M., Burnett J.C. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. Am J Physiol 1989, 257:R917-R923.
201. Redfield M.M., Edwards B.S., McGoon M.D., Heublein D.M., Aarhus L.L., Burnett J.C. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 1989, 80:651-657.
202. Richards A.M., Nicholls M.G., Ikram H., Webster M.W., Yandle T.G., Espiner E.A. Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985, 1:545-549.
203. Richards A.M., Nicholls M.G., Espiner E.A., et al. Effects of alpha-human atrial natriuretic peptide in essential hypertension. Hypertension 1985, 7:812-817.
204. Stingo A.J., Clavell A.L., Heublein D.M., Wei C.M., Pittelkow M.R., Burnett J.C. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992, 263:H1318-H1321.
205. Stingo A.J., Clavell A.L., Aarhus L., Burnett J.C. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992, 262:H308-H312.
206. Wei C.M., Aarhus L.L., Miller V.M., Burnett J.C. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993, 264:H71-H73.
207. Wei C.M., Kim C.H., Miller V.M., Burnett J.C. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92:2048-2052.